Prescrire Int. 2016 Jun;25(172):153.
In addition to the risk of cardiovascular events and neurological disorders, sympathomimetic decongestants have teratogenic potential, albeit weak, when taken during the first trimester of pregnancy, probably through disruption of the vascular system of the embryo and the pregnant woman. In the second and third trimesters of pregnancy, the fetus is exposed to the same adverse effects as the mother.
除了有心血管事件和神经紊乱的风险外,拟交感神经减充血剂在妊娠头三个月服用时具有致畸潜力,尽管这种潜力较弱,可能是通过破坏胚胎和孕妇的血管系统。在妊娠的第二和第三个月,胎儿会受到与母亲相同的不良影响。